DD296613A5 - Antioagulanz enthaltendes mittel - Google Patents

Antioagulanz enthaltendes mittel Download PDF

Info

Publication number
DD296613A5
DD296613A5 DD90342784A DD34278490A DD296613A5 DD 296613 A5 DD296613 A5 DD 296613A5 DD 90342784 A DD90342784 A DD 90342784A DD 34278490 A DD34278490 A DD 34278490A DD 296613 A5 DD296613 A5 DD 296613A5
Authority
DD
German Democratic Republic
Prior art keywords
leu
giu
lys
ser
asp
Prior art date
Application number
DD90342784A
Other languages
German (de)
English (en)
Inventor
Christian Reutelingsperger
Original Assignee
��������@��������@����������@���k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ��������@��������@����������@���k�� filed Critical ��������@��������@����������@���k��
Publication of DD296613A5 publication Critical patent/DD296613A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DD90342784A 1989-07-15 1990-07-13 Antioagulanz enthaltendes mittel DD296613A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3923500 1989-07-15

Publications (1)

Publication Number Publication Date
DD296613A5 true DD296613A5 (de) 1991-12-12

Family

ID=6385154

Family Applications (1)

Application Number Title Priority Date Filing Date
DD90342784A DD296613A5 (de) 1989-07-15 1990-07-13 Antioagulanz enthaltendes mittel

Country Status (9)

Country Link
US (1) US5296467A (fr)
EP (1) EP0409052B1 (fr)
JP (1) JPH03135920A (fr)
AT (1) ATE89169T1 (fr)
CA (1) CA2021146A1 (fr)
DD (1) DD296613A5 (fr)
DE (2) DE4022010A1 (fr)
DK (1) DK0409052T3 (fr)
ES (1) ES2055234T3 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571667A (en) * 1987-10-01 1996-11-05 Chu; Albert E. Elongated membrane flow-through diagnostic device and method
CA2116227A1 (fr) * 1991-09-23 1993-04-01 Christine A. Towle Annexine xi
DE4341274A1 (de) * 1993-12-03 1995-06-14 Boehringer Ingelheim Int Beschichtung von medizinischen Materialien mit Annexinen
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US6180596B1 (en) * 1995-05-18 2001-01-30 Wisconsin Alumni Research Foundation Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities
IL140700A0 (en) 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
NZ508950A (en) 1998-07-13 2003-10-31 Univ Texas Cancer treatment methods using antibodies to aminophospholipids
WO2001059455A2 (fr) * 2000-02-08 2001-08-16 Acspurt B.V. Materiau et procede pour l'immobilisation d'especes bioactives
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
JP2004528025A (ja) * 2001-02-21 2004-09-16 サーロメッド・インコーポレーテッド 修飾されたアネキシン蛋白質及び血栓症を防ぐための方法
US6982154B2 (en) * 2002-02-21 2006-01-03 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
US7893222B2 (en) * 2002-12-20 2011-02-22 University Of Houston Introduction of structural affinity handles as a tool in selective nucleic acid separations
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
WO2008104861A1 (fr) * 2007-02-27 2008-09-04 Karine Berthet Procédé pour le traitement d'un sujet ayant une insuffisance vasculaire dans la partie supérieure du corps, notamment une insuffisance vasculaire cérébrale ou un trouble vasculaire oculaire
EP2570458B1 (fr) 2009-02-09 2019-05-15 Mitsubishi Engineering-Plastics Corporation Composition de résine polycarbonate et produit formé à partir de celle-ci
MX2018009863A (es) 2010-08-30 2022-06-14 Evogene Ltd Polinucleotidos y polipeptidos aislados, y metodos para utilizarlos para aumentar la eficacia en el uso de nitrogeno, rendimiento, tasa de crecimiento, vigor, biomasa, contenido de aceite y/o tolerancia al estres abiotico.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315000A1 (de) * 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
DE3418888A1 (de) * 1984-05-21 1985-11-21 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
DE3533516A1 (de) * 1984-09-21 1986-04-03 Boehringer Ingelheim KG, 6507 Ingelheim Blutgerinnungshemmende proteine, verfahren zur herstellung sowie deren verwendung
CA1265446A (fr) * 1985-09-30 1990-02-06 Masahiro Maki Substance anticoagulante, procede de preparation et anticoagulant comprenant ces substances actives
JPH0689014B2 (ja) * 1986-01-21 1994-11-09 興和株式会社 トロンビン結合性物質およびその製法
JP2593500B2 (ja) * 1986-06-24 1997-03-26 ノルデイスク ゲントフテ エー／エス ▲ｖｉｉｉ▼因子フラグメントの凝固活性複合物の製造方法
DE3710430A1 (de) * 1987-03-28 1989-01-19 Boehringer Ingelheim Int Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
DE3737239A1 (de) * 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
DE4021979A1 (de) * 1989-07-15 1991-01-31 Boehringer Ingelheim Int Verfahren zur reinigung von annexinen

Also Published As

Publication number Publication date
US5296467A (en) 1994-03-22
CA2021146A1 (fr) 1991-01-16
JPH03135920A (ja) 1991-06-10
DK0409052T3 (da) 1993-06-07
EP0409052B1 (fr) 1993-05-12
ES2055234T3 (es) 1994-08-16
DE4022010A1 (de) 1991-01-17
EP0409052A2 (fr) 1991-01-23
DE59001418D1 (de) 1993-06-17
EP0409052A3 (en) 1991-09-18
ATE89169T1 (de) 1993-05-15

Similar Documents

Publication Publication Date Title
EP0409052B1 (fr) Agent contenant un anticoagulant
DE3884622T2 (de) Schmiermittelzubereitung zur behandlung von rheuma.
DE69635271T2 (de) Verfahren zu behandlung von amyloidosis
EP0648114B1 (fr) Liposomes, procede concernant leur fabrication, et leur utilisation dans la fabrication d'un medicament
DE69923987T2 (de) Synergistische antimikrobielle, dermatologische und ophtahalmologische zubereitung, die ein chlorit und wasserstoffperoxid enthalten
DE3687899T2 (de) Verfahren und zusammensetzung zur regelung des serumkalziumspiegels von saeugetieren.
DE69708121T3 (de) Halogenid-enthaltende insulinzubereitungen
EP0500602B1 (fr) Agent de neutralisation de l'activite procoagulante associee aux cellules tumorales
DE69725704T2 (de) Konservierungssysteme fur cyclodextrine enthaltende arzneimittel
EP0130550A2 (fr) Composition pharmaceutique à base de l'héparine et de tensionactifs excerçant un effet sur les muqueuses de la bouche, du nez et/ou de la gorge
EP1673068B1 (fr) Composition cosmetique favorisant le transport d'oxygene dans la peau
CA2345414A1 (fr) Gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs afin de promouvoir la secretion lacrymale ou pour traiter la keratoconjonctivite
CH641046A5 (de) Verfahren zur herstellung bestaendiger urokinasemittel.
DE2745695A1 (de) Pharmazeutische kombination, verfahren zu ihrer herstellung und ihre verwendung
DE69024053T2 (de) Behandlung zur ermässigung von ödem und muskelschäden.
DE69008258T2 (de) S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates.
EP0193175A2 (fr) Hirudines modifiées, leur procédé de préparation et agents pharmaceutiques les contenant
DE69736554T2 (de) Ophthalmische arzneimittelzusammenstellung
WO1989006962A1 (fr) Agent contenant de la sulfadiazine d'argent pour traitement topique externe
DE69634905T2 (de) Phosphnatanaloge von Mannose-6-phosphate und deren Verwendung zur Förderung der Heilung von Wunden oder fibrotischen Störungen mit verminderter Narbenbildung
WO2003077941A1 (fr) Utilisation d'un ou de plusieurs liants d'oxygene naturels ou modifies, exempts de plasma et de constituants de la paroi cellulaire, pour le traitement externe de plaies ouvertes, notamment chroniques
DE10141018A1 (de) Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges
EP1962887B1 (fr) Procédé de détermination d'un effet anti-inflammatoire d'un peptide
DE60217060T2 (de) Pharmazeutische Zusammensetzungen, die Lungensurfactants und ein Polymyxin umfassen und verbesserte Oberflächenspannung-senkende Eigenschaften haben
EP1303294B1 (fr) Procede de traitement d'une angine de poitrine instable

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee